智通财经APP获悉，乐普生物-B(02157)午后涨超6%，截至发稿，涨5.76%，报4.41港元，成交额3357.41万港元。
消息面上，2月26日，乐普生物宣布其自主研发的创新型抗体偶联药物MRG006A联合免疫检查点抑制剂、靶向治疗药物用于晚期肝癌患者的临床试验申请，正式获国家药品监督管理局批准。这是国内首个申报临床、全球首个进入临床阶段的GPC3靶向ADC药物，本次获批标志着其从单药探索迈向联合治疗新赛道，有望为晚期肝癌患者带来更具疗效的全新方案。
国联民生证券发布研报称，MRG006A有望推动肝癌精准治疗。该行指出，乐普生物ADC布局领先，两款ADC已实现出海。MRG006A和MRG007均是基于新一代Hi-TOPi ADC平台开发的新型ADC，有望提升公司价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.